Loading...
•
Jun 30, 2022
Personalis Q2 2022 Earnings Report
Reported a decrease in revenue compared to the same quarter last year, but oncology revenue growth was strong, driven by the adoption of the NeXT Platform.
Key Takeaways
Personalis, Inc. reported a decrease in revenue for the second quarter of 2022 compared to the same period in 2021. Total revenue was $18.2 million, compared to $21.7 million in Q2 2021. However, revenue from biopharma and other customers, excluding the VA MVP, increased by 74%. The company's net loss was $27.5 million, or $0.60 per share.
Reported quarterly revenue of $18.2 million in the second quarter of 2022 compared with $21.7 million in the second quarter of 2021.
Revenue from biopharma and other customers, excluding the VA MVP, increased by 74% to $14.2 million.
Added another patent family to its molecular residual disease (MRD)-related IP portfolio.
Appointed Lonnie Shoff to the Personalis Board of Directors effective August 2, 2022.
Forward Guidance
Personalis expects total company revenue to be in the range of $62.0 million to $67.0 million for the full year of 2022. Revenue from biopharma and all other customers, excluding the VA MVP, is expected to be in the range of $55.0 million to $60.0 million. Net loss is expected to be in the range of $110.0 million to $115.0 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...